IPO-hopeful Kite Pharma inks an NIH licensing deal on hot TCR tech

Just days after GlaxoSmithKline ($GSK) barreled into a new cancer drug pact targeting the hot T-cell receptor field and a lead program at Adaptimmune, one of the pioneering rivals in the arena has partnered on similar work at the National Cancer Institute.

Santa Monica-based Kite Pharma, which recently filed for a $115 million IPO, snapped up the NIH's IP on TCRs that target the NY-ESO-1 antigen--the same expression target that GSK just partnered on--which is implicated in a variety of cancers. Kite is also developing CAR-T drugs aimed at spurring an immune-system attack against cancer cells.

Like CAR-T, TCR tech looks to genetically reengineer T cells into cancer-fighting soldiers, opening a new chapter in immuno-oncology (IO) that has quickly grabbed the attention of some key players in the cancer arena. While CAR-T looks to add a chimeric antigen receptor to the surface of T cells so that they can better destroy cancer cells, TCRs are focused on intracellular tinkering, and NY-ESO-1 looks to be the top contender among the targets for treating tumors.

According to Kite, the NCI is in a Phase II study of one drug candidate under a development agreement with the biotech. "Kite is investigating murine (mouse)-derived TCR technology platforms developed by the NCI Surgery Branch for the treatment of solid tumors under the CRADA," the biotech said in a statement. "Preclinical evaluation in the Surgery Branch of murine TCRs targeting the NY-ESO-1 antigen identified a murine TCR with comparable or enhanced activity relative to the equivalent human-based NY-ESO-1 TCR."

Kite agreed to pay the NIH a set of milestones and royalties for any successful program, but didn't spell out the details.

- here's the release

Suggested Articles

The EMA and FDA will need traditional clinical trial hurdles removed if governments want the inoculations as quickly as possible.

In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K.

Amgen and new partner Adaptive Biotechnologies are the latest pharma-biotech duo joining forces against the pandemic.